Condition: Somatostatin Receptor Positive · NETs · Lymphoma · Sponsor: ITM Solucin GmbH
The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following standard of care (SoC) in participants ≥2 to \<18 years of age with somatostatin receptor (SSTR)-positive tumors.
This description comes directly from the study's public registry record.
Shahanaz Rahman · +4989 32989866000 · kinlet@itm-radiopharma.com
Serhii Melnyk, MD · kinlet@itm-radiopharma.com
Always discuss trial participation with your own doctor first.
| The Children's Hospital of Philadelphia (CHOP) | Philadelphia, Pennsylvania, United States | Recruiting |
| University of Texas - MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Gustave Roussy Cancer Campus | Villejuif, France | Recruiting |
| Hospital Universitario Vall d'Hebron - Oncología Médica | Barcelona, Spain | Recruiting |
| Hospital General Universitario Gregorio Marañón | Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06441331